Hunan Warrant Pharmaceutical Co. Ltd. A (688799) - Net Assets
Based on the latest financial reports, Hunan Warrant Pharmaceutical Co. Ltd. A (688799) has net assets worth CN¥1.86 Billion CNY (≈ $271.91 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.53 Billion ≈ $369.58 Million USD) and total liabilities (CN¥667.46 Million ≈ $97.67 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Hunan Warrant Pharmaceutical Co. Ltd. A liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.86 Billion |
| % of Total Assets | 73.57% |
| Annual Growth Rate | 26.92% |
| 5-Year Change | 174.88% |
| 10-Year Change | N/A |
| Growth Volatility | 45.44 |
Hunan Warrant Pharmaceutical Co. Ltd. A - Net Assets Trend (2019–2024)
This chart illustrates how Hunan Warrant Pharmaceutical Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Also explore Hunan Warrant Pharmaceutical Co. Ltd. A total assets for the complete picture of this company's asset base.
Annual Net Assets for Hunan Warrant Pharmaceutical Co. Ltd. A (2019–2024)
The table below shows the annual net assets of Hunan Warrant Pharmaceutical Co. Ltd. A from 2019 to 2024. For live valuation and market cap data, see 688799 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.82 Billion ≈ $266.70 Million |
+3.07% |
| 2023-12-31 | CN¥1.77 Billion ≈ $258.75 Million |
+6.61% |
| 2022-12-31 | CN¥1.66 Billion ≈ $242.71 Million |
+12.11% |
| 2021-12-31 | CN¥1.48 Billion ≈ $216.49 Million |
+123.13% |
| 2020-12-31 | CN¥663.05 Million ≈ $97.03 Million |
+19.86% |
| 2019-12-31 | CN¥553.17 Million ≈ $80.95 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hunan Warrant Pharmaceutical Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 249.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥812.37 Million | 45.05% |
| Other Components | CN¥991.04 Million | 54.95% |
| Total Equity | CN¥1.80 Billion | 100.00% |
Hunan Warrant Pharmaceutical Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Hunan Warrant Pharmaceutical Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MannKind Corp
NASDAQ:MNKD
|
$1.09 Billion |
|
Dongguan Mentech Optical & Magnetic Co Ltd
SHE:002902
|
$1.09 Billion |
|
MillerKnoll Inc
NASDAQ:MLKN
|
$1.09 Billion |
|
Anhui Xinlong Electrical Co Ltd
SHE:002298
|
$1.09 Billion |
|
Sharda Cropchem Limited
NSE:SHARDACROP
|
$1.09 Billion |
|
tonies SE
F:TNIE
|
$1.09 Billion |
|
Aussie Broadband Ltd
AU:ABB
|
$1.09 Billion |
|
MPC Container Ships ASA
OL:MPCC
|
$1.09 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hunan Warrant Pharmaceutical Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,723,509,650 to 1,803,406,936, a change of 79,897,286 (4.6%).
- Net income of 164,317,286 contributed positively to equity growth.
- Dividend payments of 86,348,949 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥164.32 Million | +9.11% |
| Dividends Paid | CN¥86.35 Million | -4.79% |
| Other Changes | CN¥1.93 Million | +0.11% |
| Total Change | CN¥- | 4.64% |
Book Value vs Market Value Analysis
This analysis compares Hunan Warrant Pharmaceutical Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.96x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 7.23x to 2.96x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥7.87 | CN¥56.86 | x |
| 2020-12-31 | CN¥9.43 | CN¥56.86 | x |
| 2021-12-31 | CN¥11.27 | CN¥56.86 | x |
| 2022-12-31 | CN¥12.16 | CN¥56.86 | x |
| 2023-12-31 | CN¥13.12 | CN¥56.86 | x |
| 2024-12-31 | CN¥19.23 | CN¥56.86 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hunan Warrant Pharmaceutical Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.11%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.63%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 1.36x
- Recent ROE (9.11%) is below the historical average (14.42%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 20.97% | 14.07% | 0.97x | 1.54x | CN¥60.69 Million |
| 2020 | 21.87% | 15.26% | 1.03x | 1.39x | CN¥78.73 Million |
| 2021 | 10.87% | 14.02% | 0.64x | 1.21x | CN¥12.81 Million |
| 2022 | 11.45% | 14.14% | 0.64x | 1.26x | CN¥23.14 Million |
| 2023 | 12.26% | 14.75% | 0.66x | 1.26x | CN¥38.97 Million |
| 2024 | 9.11% | 11.63% | 0.57x | 1.36x | CN¥-16.02 Million |
Industry Comparison
This section compares Hunan Warrant Pharmaceutical Co. Ltd. A's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,691,234,838
- Average return on equity (ROE) among peers: 6.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hunan Warrant Pharmaceutical Co. Ltd. A (688799) | CN¥1.86 Billion | 20.97% | 0.36x | $1.09 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $903.62 Million | 4.28% | 2.45x | $1.16 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.22 Billion | 5.35% | 1.27x | $441.99 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $9.87 Billion | 20.71% | 0.25x | $5.01 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.80 Billion |
| Wedge Industrial Co Ltd (000534) | $1.15 Billion | 11.42% | 1.59x | $3.04 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $9.03 Billion | 25.71% | 0.43x | $13.75 Billion |
| Hainan Haiyao Co Ltd (000566) | $275.57 Million | 17.28% | 1.12x | $947.33 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $231.22 Million | -38.13% | 1.23x | $389.67 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $4.29 Billion | 2.31% | 2.07x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $18.87 Billion | 8.83% | 0.08x | $3.32 Billion |
About Hunan Warrant Pharmaceutical Co. Ltd. A
Hunan Warrant Pharmaceutical Co.,Ltd manufactures and sells pharmaceutical products. It offers medicines in the areas of digestive, berating, anti-infection, gynecology, cardiovascular, cerebrovascular, immunology and nephrology, and other fields. Hunan Warrant Pharmaceutical Co.,Ltd was founded in 2001 and is based in Changsha, China.